Other medication classes used in diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

Click through to read more on this announcement

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.

The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.

Starting people on bevacizumab and switching to aflibercept only when necessary keeps costs down without compromising treatment efficacy for people with diabetic macular edema, shows a randomized trial.

Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.

Subcutaneous mini-dose glucagon reverses hypoglycemia more effectively than oral glucose tablets and helps adults with type 1 diabetes complete Ramadan fasts, shows a randomized crossover trial.

Researchers report that the antihypertensive medication verapamil preserves beta-cell function and reduces insulin needs in adults with type 1 diabetes during up to 2 years of treatment.

The dual Ang-2 and VEGF-A pathway inhibitor faricimab is noninferior to aflibercept for improving visual acuity in people with diabetic macular edema, and an individualized dosing strategy could help reduce treatment burden, suggest findings from the YOSEMITE and RHINE trials.

Reducing blood pressure may be an effective strategy for the prevention of new-onset type 2 diabetes, suggest researchers from the Blood Pressure Lowering Treatment Trialists’ Collaboration.

Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.

The duration of statin therapy in people with type 2 diabetes may be even more important than the intensity or the achieved level of low-density lipoprotein cholesterol for preventing cardiovascular events, research suggests.

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.